Clinical care pathway to detect advanced liver disease in patients with type 2 diabetes through automated fibrosis score calculation and electronic reminder messages: a randomised controlled trial

Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection†‡

Sterling, R. K., Lissen, E., Clumeck, N., Sola, R., Correa, M. C., Montaner, J., S. Sulkowski, M., Torriani, F. J., Dieterich, D. T., Thomas, D. L., et al. (2006) · Hepatology · doi:10.1002/hep.21178 · Cited by 5,021 · see citing works

EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease

(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836 · see citing works

A Simple Noninvasive Index Can Predict Both Significant Fibrosis and Cirrhosis in Patients With Chronic Hepatitis C

Wai, C.-T., Greenson, J. K., Fontana, R. J., Kalbfleisch, J. D., Marrero, J. A., Conjeevaram, H. S., & Lok, A. S.-F. (2003) · Hepatology · doi:10.1053/jhep.2003.50346 · Cited by 4,406 · see citing works

Non-alcoholic fatty liver disease

Powell, E. E., Wong, V. W.-S., & Rinella, M. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32511-3 · Cited by 2,789 · see citing works

AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease

Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667 · cited 1× · see citing works

The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis

Younossi, Z. M., Golabi, P., de Avila, L., Paik, J. M., Srishord, M., Fukui, N., Qiu, Y., Burns, L., Afendy, A., & Nader, F. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.06.021 · Cited by 2,235 · see citing works

Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis

Taylor, R. S., Taylor, R. J., Bayliss, S., Hagström, H., Nasr, P., Schattenberg, J. M., Ishigami, M., Toyoda, H., Wai-Sun Wong, V., Peleg, N., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.043 · Cited by 1,069 · see citing works

American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings

Cusi, K., Isaacs, S., Barb, D., Basu, R., Caprio, S., Garvey, W. T., Kashyap, S., Mechanick, J. I., Mouzaki, M., Nadolsky, K., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.03.010 · Cited by 1,021 · see citing works

Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis

McPherson, S., Hardy, T., Dufour, J.-F., Petta, S., Romero-Gomez, M., Allison, M., Oliveira, C. P., Francque, S., Van Gaal, L., Schattenberg, J. M., et al. (2017) · American Journal of Gastroenterology · doi:10.1038/ajg.2016.453 · Cited by 945 · see citing works

The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality

Karlsen, T. H., Sheron, N., Zelber-Sagi, S., Carrieri, P., Dusheiko, G., Bugianesi, E., Pryke, R., Hutchinson, S. J., Sangro, B., Martin, N. K., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)01701-3 · Cited by 652 · see citing works

Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease

Kanwal, F., Shubrook, J. H., Adams, L. A., Pfotenhauer, K., Wai-Sun Wong, V., Wright, E., Abdelmalek, M. F., Harrison, S. A., Loomba, R., Mantzoros, C. S., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.07.049 · Cited by 618 · see citing works

Noninvasive biomarkers in NAFLD and NASH — current progress and future promise

Wong, V. W., Adams, L. A., de Lédinghen, V., Wong, G. L., & Sookoian, S. C. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0014-9 · Cited by 617 · see citing works

Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography

Wong, V. W., Chu, C. W., Wong, G. L., Chan, R., Chim, A. M., Ong, A., Yeung, D. K., Yiu, K. K., Chu, S. H.-T., Woo, J., et al. (2011) · Gut · doi:10.1136/gutjnl-2011-300342 · Cited by 491 · see citing works

Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study

Kwok, R., Choi, K. C., Wong, G. L., Zhang, Y., Chan, H. L.-Y., Luk, A. O. Y., Shu, S. S., Chan, A. W. H., Yeung, M. W., Chan, J. C. N., et al. (2015) · Gut · doi:10.1136/gutjnl-2015-309265 · Cited by 480 · see citing works

Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis

Mózes, F. E., Lee, J. A., Selvaraj, E. A., Jayaswal, A. N. A., Trauner, M., Boursier, J., Fournier, C., Staufer, K., Stauber, R. E., Bugianesi, E., et al. (2022) · Gut · doi:10.1136/gutjnl-2021-324243 · Cited by 477 · see citing works

Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease

Srivastava, A., Gailer, R., Tanwar, S., Trembling, P. M., Parkes, J., Rodger, A. J., Suri, D., Thorburn, D., Sennett, K., Morgan, S., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.03.033 · Cited by 449 · see citing works

Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening

Lomonaco, R., Godinez Leiva, E., Bril, F., Shrestha, S., Mansour, L., Budd, J., Portillo Romero, J., Schmidt, S., Chang, K.-L., Samraj, G., et al. (2021) · Diabetes Care · doi:10.2337/dc20-1997 · Cited by 354 · see citing works

The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?

Lazarus, J. V., Mark, H. E., Villota‐Rivas, M., Palayew, A., Carrieri, P., Colombo, M., Ekstedt, M., Esmat, G., George, J., Marchesini, G., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.10.025 · Cited by 270 · see citing works

Repeated FIB-4 measurements can help identify individuals at risk of severe liver disease

Hagström, H., Talbäck, M., Andreasson, A., Walldius, G., & Hammar, N. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.06.007 · Cited by 199 · see citing works

Unified interpretation of liver stiffness measurement by M and XL probes in non-alcoholic fatty liver disease

Wong, V. W., Irlès, M., Wong, G. L., Shili, S., Chan, A. W. H., Merrouche, W., Shu, S. S., Foucher, J., Bail, B. L., Chan, W., et al. (2019) · Gut · doi:10.1136/gutjnl-2018-317334 · Cited by 174 · see citing works

Improved Surveillance for Hepatocellular Carcinoma With a Primary Care–Oriented Clinical Reminder

Beste, L. A., Ioannou, G. N., Yang, Y. H., Chang, M. F., Ross, D. B., & Dominitz, J. A. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.04.033 · Cited by 119 · see citing works

A Global Survey of Physicians Knowledge About Nonalcoholic Fatty Liver Disease

Younossi, Z. M., Ong, J. P., Takahashi, H., Yilmaz, Y., Eguc`hi, Y., El Kassas, M., Buti, M., Diago, M., Zheng, M.-H., Fan, J.-G., et al. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.06.048 · Cited by 115 · see citing works

Screening for non‐alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography

Lai, L. L., Yusoff, W. N. I. W., Vethakkan, S. R., Mustapha, N. R. N., Mahadeva, S., & Chan, W. (2018) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.14577 · Cited by 106 · see citing works

Intelligent liver function testing (iLFT): A trial of automated diagnosis and staging of liver disease in primary care

Dillon, J. F., Miller, M. H., Robinson, E. M., Hapca, A., Rezaei-Hemami, M., Weatherburn, C., McIntyre, P. G., Bartlett, W. A., Donnan, P. T., Boyd, K., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.05.033 · Cited by 89 · see citing works

Diabetes and cirrhosis: Current concepts on diagnosis and management

Castéra, L., & Cusi, K. J. (2023) · Hepatology · doi:10.1097/hep.0000000000000263 · Cited by 87 · see citing works

Management of NAFLD in primary care settings

Wong, V. W., Zelber‐Sagi, S., Cusi, K. J., Carrieri, P., Wright, E. E., Crespo, J., & Lazarus, J. V. (2022) · Liver International · doi:10.1111/liv.15404 · Cited by 82 · see citing works

Serial Transient Elastography Examinations to Monitor Patients With Type 2 Diabetes: A Prospective Cohort Study

Lee, H. W., Wong, G. L., Kwok, R., Choi, K. C., Chan, C. K., Shu, S. S., Leung, J. K., Chim, A. M., Luk, A. O. Y., Ronald, C. W., et al. (2020) · Hepatology · doi:10.1002/hep.31142 · Cited by 80 · see citing works

Structured Early detection of Asymptomatic Liver Cirrhosis: Results of the population-based liver screening program SEAL

Labenz, C., Arslanow, A., Nguyen-Tat, M., Nagel, M., Wörns, M., Reichert, M., Heil, F. J., Mainz, D., Zimper, G., Römer, B., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.04.009 · Cited by 58 · see citing works

Risk of liver‐related events by age and diabetes duration in patients with diabetes and nonalcoholic fatty liver disease

Zhang, X., Wong, G. L., Yip, T. C., Cheung, J. T. K., Tse, Y., Hui, V. W., Lin, H., Lai, J. C., Chan, H. L., Kong, A. P. S., et al. (2022) · Hepatology · doi:10.1002/hep.32476 · Cited by 56 · see citing works

Diagnostic Accuracy of Noninvasive Fibrosis Scores in a Population of Individuals With a Low Prevalence of Fibrosis

Mahady, S. E., Macaskill, P., Craig, J. C., Wong, G. L., Chu, C. W., Chan, H. L., George, J., & Wong, V. W. (2017) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.02.031 · Cited by 52 · see citing works

Age and the relative importance of liver-related deaths in nonalcoholic fatty liver disease

Lin, H., Yip, T. C., Zhang, X., Li, G., Tse, Y., Hui, V. W., Liang, L. Y., Lai, J. C., Chan, S. L., Chan, H. L., et al. (2023) · Hepatology · doi:10.1002/hep.32633 · Cited by 52 · see citing works

Local care and treatment of liver disease (LOCATE) – A cluster-randomized feasibility study to discover, assess and manage early liver disease in primary care

El-Gohary, M., Moore, M. V., Roderick, P. J., Watkins, E., Dash, J., Reinson, T., Newell, C., Kim, M., Stuart, B. L., Becque, T., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0208798 · Cited by 41 · see citing works

Performance of American Gastroenterological Association Clinical Care Pathway for the risk stratification of patients with nonalcoholic fatty liver disease in the US population

Udompap, P., Therneau, T. M., Canning, R. E., Benson, J. T., & Allen, A. M. (2023) · Hepatology · doi:10.1002/hep.32739 · Cited by 37 · see citing works

EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).

Tacke, F., Horn, P., Wai-Sun Wong, V., Ratziu, V., Bugianesi, E., Francque, S., Zelber-Sagi, S., Valenti, L., Roden, M., Schick, F., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.031 · Cited by 2,210 · see citing works

EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

(2024) · Obesity Facts · doi:10.1159/000539371 · Cited by 510 · see citing works

Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association

Cusi, K. J., Abdelmalek, M. F., Apovian, C. M., Balapattabi, K., Bannuru, R. R., Barb, D., Bardsley, J. K., Beverly, E. A., Corbin, K. D., ElSayed, N. A., et al. (2025) · Diabetes Care · doi:10.2337/dci24-0094 · Cited by 396 · see citing works

Metabolic dysfunction-associated steatotic liver disease in adults

Huang, D. Q., Wong, V. W., Rinella, M. E., Boursier, J., Lazarus, J. V., Yki‐Järvinen, H., & Loomba, R. S. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00599-1 · Cited by 336 · see citing works

Vibration-controlled transient elastography scores to predict liver-related events in steatotic liver disease

Lin, H., Lee, H. W., Yip, T. C.-F., Tsochatzis, E., Petta, S., Bugianesi, E., Yoneda, M., Zheng, M.-H., Hagström, H., Boursier, J., et al. (2024) · JAMA · doi:10.1001/jama.2024.1447 · Cited by 250 · see citing works

The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment

Chan, S. L., Sun, H., Xu, Y., Zeng, H., El‐Serag, H. B., Lee, J. M., Schwartz, M., Finn, R. S., Seong, J., Wang, X. W., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01042-6 · Cited by 247 · see citing works

The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease

Eslam, M., Fan, J., Yu, M., Wong, V. W., Cua, I. H., Liu, C., Tanwandee, T., Gani, R. A., Seto, W., Alam, S., et al. (2025) · Hepatology International · doi:10.1007/s12072-024-10774-3 · Cited by 186 · see citing works

Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease

Wang, Y., Song, S. J., Jiang, Y., Lai, J. C., Wong, G. L., Wong, V. W., & Yip, T. C. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0246 · Cited by 32 · see citing works

Projected Trends in Metabolic Dysfunction–Associated Steatotic Liver Disease Mortality Through 2040

Zhang, X., Linden, S., Levesley, C. R., He, X., Yang, Z., Barnet, S., Cheung, R. C., Ji, F., & Nguyen, M. H. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.16367 · Cited by 33 · see citing works

Use of non‐invasive diagnostic tools for metabolic dysfunction‐associated steatohepatitis: A qualitative exploration of challenges and barriers

Tsochatzis, E. A., Valenti, L. V. C., Thiele, M. S., Péloquin, S., Lazure, P., Masson, M. H., Allen, A. M., Lazarus, J. V., Noureddin, M., Rinella, M. E., et al. (2024) · Liver International · doi:10.1111/liv.15941 · Cited by 31 · see citing works

Non-invasive risk-based surveillance of hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease

Lai, J. C., Yang, B., Lee, H. W., Lin, H., Tsochatzis, E. A., Petta, S., Bugianesi, E., Yoneda, M., Zheng, M., Hagström, H., et al. (2025) · Gut · doi:10.1136/gutjnl-2025-334981 · Cited by 32 · see citing works

Screening for liver fibrosis: lessons from colorectal and lung cancer screening

Thiele, M. S., Kamath, P. S., Graupera, I., Castells, A., de Koning, H. J., Serra‐Burriel, M., Lammert, F., & Ginès, P. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-00907-2 · Cited by 30 · see citing works

Clinical Care Pathway for the Risk Stratification and Management of Patients With Metabolic Dysfunction–Associated Steatotic Liver Disease

Kanwal, F., Bril, F., Wong, V. W., Adams, L. A., Pfotenhauer, K. M., SKOLNIK, N., Wright, E. E., Eckel, R. H., Noureddin, M., Loomba, R. S., et al. (2026) · Gastroenterology · doi:10.1053/j.gastro.2026.01.047 · Cited by 35 · see citing works

Diagnosis and non‐invasive assessment of MASLD in type 2 diabetes and obesity

Chan, W., Petta, S., Noureddin, M., Goh, G. B., & Wong, V. W. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17866 · Cited by 25 · see citing works

Metabolic dysfunction‐associated steatotic liver disease, insulin resistance and hepatocellular carcinoma: A deadly triad

Caturano, A., Erul, E., Nilo, R., Nilo, D., Russo, V., Rinaldi, L., Acierno, C., Akkuş, E., Koudelková, K., Cerini, F., et al. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70132 · Cited by 25 · see citing works

Population screening for cirrhosis

Thiele, M. S., Pose, E., Juanola, A., Mellinger, J. L., & Ginès, P. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000512 · Cited by 25 · see citing works

MAFLD in adults: non-invasive tests for diagnosis and monitoring of MAFLD

Chan, W., Wong, V. W., Adams, L. A., & Nguyen, M. H. (2024) · Hepatology International · doi:10.1007/s12072-024-10661-x · Cited by 24 · see citing works

A call for doubling the diagnostic rate of at-risk metabolic dysfunction-associated steatohepatitis

Lazarus, J. V., Brennan, P., Mark, H. E., Alazawi, W., Allen, A. M., Byrne, C. D., Castéra, L., Caussy, C., Cusi, K. J., Grajower, M. M., et al. (2025) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2025.101320 · Cited by 27 · see citing works

Screening for advanced steatotic liver disease

Johansen, S., Åberg, F. O., Tsochatzis, E. A., & Krag, A. A. (2025) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(25)00097-4 · Cited by 19 · see citing works

LiverRisk score: An accurate, cost-effective tool to predict fibrosis, liver-related, and diabetes-related mortality in the general population

Liu, S., Chen, X., Jiang, X., Yin, X., Fekadu, G., Liu, C., He, Y., Chen, H., Ni, W., Wang, R., et al. (2024) · Med · doi:10.1016/j.medj.2024.03.003 · Cited by 18 · see citing works

Detecting at-risk steatotic liver disease and liver fibrosis in the community

Adams, L. A., Thiele, M. S., & Tsochatzis, E. A. (2025) · Hepatology · doi:10.1097/hep.0000000000001400 · Cited by 14 · see citing works

MASLD: a disease in flux

Allen, A. M., Arab, J. P., & Wong, V. W. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-00990-5 · Cited by 13 · see citing works

Managing MASLD Through Preventive Hepatology: Integrating Policy Reform, Public Health and Personalised Care

Younossi, Z. M., Wong, V. W., Tsochatzis, E. A., Castéra, L., Betel, M., Henry, L. L., & Zelber‐Sagi, S. (2025) · Liver International · doi:10.1111/liv.70311 · Cited by 10 · see citing works

Baseline and Dynamic MAF-5 Score to Predict Liver Fibrosis and Liver-Related Events in General Population With MASLD

Liu, S., Jiang, X., Fu, J., Zhong, V. W., Zhong, V. W., & Qi, X. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.07.005 · Cited by 8 · see citing works

Kidney Disease: Improving Global Outcomes Summit Recommendations on Implementation of Diabetes Management in CKD: From Primary to Data-Driven Collaborative Care

Li, P. K., Cheung, M., Chow, K., Leung, M. K. W., Lim, L., Lui, J. N. M., Luk, A. O. Y., Manski-Nankervis, J.-A., Seidu, S., Tandon, N., et al. (2025) · Kidney International Reports · doi:10.1016/j.ekir.2025.06.010 · Cited by 8 · see citing works

Histological severity and hepatic outcomes in patients with metabolic dysfunction-associated steatotic liver disease and discrepant FIB-4 and liver stiffness measurement

Rabbat, J., Yang, B., Lee, H. W., Lin, H., Tsochatzis, E. A., Petta, S., Bugianesi, E., Yoneda, M., Zheng, M., Hagström, H., et al. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0888 · Cited by 8 · see citing works

Using NIS2+™ to identify at-risk MASH in clinical trials

Lai, J. C., & Wong, V. W. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.11.009 · Cited by 7 · see citing works

Diagnostic innovation and models of care to improve fibrosis detection and risk stratification in steatotic liver disease

Pugliese, N., White, T. M., Brennan, P., Pannain, S., Hagström, H., Michel, M., Rice-Duek, L., Targher, G., Caussy, C., Dillon, J. F., et al. (2026) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2026.101722 · Cited by 6 · see citing works

Screening patients in general practice for advanced chronic liver disease using an innovative IT solution: The Liver Toolkit

Prince, D. S., Hoque, S., Kim, C., Maher, S., Miller, J., Chomley, P., Pritchard‐Jones, J., Spruce, S., McGarry, N., Baker, D., et al. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000482 · Cited by 6 · see citing works

Algorithms for Early Detection of Silent Liver Fibrosis in the Primary Care Setting

Bech, K., Lindvig, K. P., Thiele, M. S., & Castéra, L. (2024) · Seminars in Liver Disease · doi:10.1055/s-0043-1778127 · Cited by 6 · see citing works

Care Pathways for Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD ): A State‐of‐The‐Art Review

van Eekhout, K. M. A., Broekman, L. D., de Jong, V., Michel, M. S., Grobbee, R., Maya‐Miles, D., Romero‐Gómez, M., Muris, J. W. M., Mendive, J. M., Vali, Y., et al. (2026) · Liver International · doi:10.1111/liv.70603 · Cited by 5 · see citing works

Validated Early Detection Metrics Reduce the Population Requiring Liver Fibrosis Screening

van Kleef, L. A., Pustjens, J., SCHNEIDER, C., Pera, G., Torán‐Monserrat, P., Michel, M., Schneider, K. M., Holleboom, A. G., Cabezas, M. C., Tushuizen, M. E., et al. (2026) · Gastroenterology · doi:10.1053/j.gastro.2026.06.003 · Cited by 4 · see citing works

Spotting undiagnosed significant liver fibrosis in the general population: impact on subsequent clinical care: Editorial on “Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis”

Peng, N., Wang, M. Y., Song, S. J., & Yip, T. C. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0737 · Cited by 4 · see citing works

7. Management of metabolic dysfunction-associated steatotic liver disease (MASLD) in type 2 diabetes

Colagiuri, S., & Ceriello, A. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112151 · Cited by 3 · see citing works

Considerations and clinical utility of referral pathways for early detection of liver disease in at-risk populations

Pustjens, J., Brouwer, W. P., Ayada, I., Janssen, H. L. A., & van Kleef, L. A. (2025) · World Journal of Gastroenterology · doi:10.3748/wjg.v31.i37.107665 · Cited by 4 · see citing works

Barriers and facilitators to liver fibrosis screening: Perspectives and practices of Canadian primary care physicians

Dinh, D. A., Betel, M., Swain, M. G., Lazarus, J. V., Joshi, S., Cusi, K. J., Kim, J. W., Jung, H.-M., Dale, C., Burnside, J., et al. (2025) · Canadian Liver Journal · doi:10.3138/canlivj-2025-0026 · Cited by 3 · see citing works

ATG9A-PLA2G6 axis reprograms phospholipid metabolism to drive metabolic liver disease and hepatocellular carcinoma

Zhu, Q., Gu, Y., Gao, Y., Zhao, X., & Zhang, L. (2025) · Autophagy · doi:10.1080/15548627.2025.2601035 · Cited by 3 · see citing works

Towards unification of liver stiffness measurement cutoffs: Editorial on “Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis”

Zhang, Y., & Wong, V. W. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0766 · Cited by 3 · see citing works

Adoption and validation of the European Association for the Study of the Liver algorithm for the noninvasive diagnosis of advanced fibrosis in metabolic dysfunction-associated steatotic liver disease in low-resource South Asian settings

Mettananda, C. D., Ranawaka, C. K., Egodage, T., Dantanarayana, C., Fernando, R., Ranaweera, L., Kottahachchi, D., Siriwardhana, S., Pathmeswaran, A., Dassanayake, A. S., et al. (2026) · PLoS ONE · doi:10.1371/journal.pone.0341364 · Cited by 2 · see citing works

Two-step care pathways for advanced MASLD in primary and hospital care: A multicenter study

Driessen, S., van Son, K. C., Riemersma, T. R., Stramigioli, E., Haverkamp, G. L. G., Denters, M. J., Alblas, G., Tjwa, E. T. T. L., Hanssen, N. M. J., Pinto‐Sietsma, S., et al. (2026) · Hepatology Communications · doi:10.1097/hc9.0000000000000976 · Cited by 2 · see citing works

The role of primary care in response to the global liver disease syndemic: a Lancet Gastroenterology & Hepatology Commission

Jarvis, H., Brennan, P., Casanovas, T., Casler, K., Desai, M., Evans, P. H., Dillon, J. F., Grattagliano, I., Hallsworth, K., Hebditch, V., et al. (2026) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(26)00015-4 · Cited by 3 · see citing works

Screening and diagnosis of liver disease in diabetes: a guide and evidence-based assessment

Qadri, S. U. (2026) · Diabetologia · doi:10.1007/s00125-026-06816-0 · Cited by 2 · see citing works

MAFLD/MASLD: Past, Present, and Future

Wong, V. W. (2026) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.70619 · Cited by 2 · see citing works

Letter regarding “Waiting for the changes after the adoption of steatotic liver disease”

Yew, K. C., Wong, S. H., Wong, V. W., & Oon, H. H. B. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2023.0472 · Cited by 2 · see citing works

Screening for Metabolic Dysfunction–Associated Steatotic Liver Disease in Patients With Type 2 Diabetes: Are We Doing Enough?

Kim, S. H., Hui, G., Pike, C. W., Jackson, M. L., Levine, M., & Kwo, P. Y. (2025) · Diabetes Spectrum · doi:10.2337/ds25-0028 · Cited by 1 · see citing works

Large-Scale Evaluation and Liver Disease Risk Prediction in Finland’s National Electronic Health Record System: Feasibility Study Using Real-World Data

Männikkö, V., Tommola, J., Tikkanen, E., Hätinen, O.-P., & Åberg, F. O. (2025) · JMIR Medical Informatics · doi:10.2196/62978 · Cited by 1 · see citing works

Editorial: Noninvasive tests for metabolic dysfunction‐associated steatotic liver disease: A refinement of the Nash‐FibroTest for type 2 diabetes mellitus

Liu, C. (2023) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17706

Editorial: Assessing advanced fibrosis in metabolic‐associated steatotic liver disease—the MAFLD fibrosis score. Authors' reply

Cheung, J. T. K., Chan, W., Zheng, M., & Wong, V. W. (2023) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17774

Correspondence to editorial on “Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis”

Kim, H. Y., Choi, M., & Jun, D. W. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0777

Algorithms for Risk Stratification in Patients with Metabolic Dysfunction-Associated Steatohepatitis

Armandi, A., Bugianesi, E., Loomba, R. S., & Caussy, C. (2026) · Clinics in Liver Disease · doi:10.1016/j.cld.2025.12.005

Acceptability of an integrated care program to identify patients at risk of advanced chronic liver disease in Australian primary care settings

O'Callaghan, C., Williamson, M., Prince, D. S., Putra, A. D. M., Miller, J., Chomley, P., & Barr, M. (2026) · Australian Journal of Primary Health · doi:10.1071/py25195

Risk stratification of MASLD/MASH in type 2 diabetes: a pragmatic endocrinology outpatient pathway

Cai, Y., Zeng, F., & Liu, C. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1922533 · Cited by 1 · see citing works

The dynamic spectrum of steatotic liver disease: the global perspective

Younossi, Z. M., Zelber‐Sagi, S., Kalligeros, M., Wajcman, D. I., Henry, L. L., Grinshpan, L. S., Israelsen, M. E., Díaz, L. A., Fan, J., Arrese, M. A., et al. (2026) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-026-01235-3

Assessing Strategies to Mitigate the Effect of Age When Using Fibrosis-4 Index to Screen for Metabolic Dysfunction–Associated Steatotic Liver Disease–Related Liver Fibrosis

Nammi, J., Southall, W. R., Huynh, K., Smith, E., Diffalha, S. A., Cusi, K. J., Gray, M., & Bril, F. (2026) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2026.09.003

Implementing MASLD Screening in Primary Care for Adults with Type 2 Diabetes: A Quality Improvement Initiative

Piekaar, D. J., Kadar, E., Kreider, K. E., & Padilla, B. I. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.09.117

A clinical care pathway to detect advanced liver disease in patients with type 2 diabetes through automated fibrosis score calculation and electronic reminder messages: a randomised controlled trial

Zhang, X., Yip, T. C., Wong, G. L., Leow, W.-X., Liang, Y., Lim, L., Li, G., Ibrahim, L., Lin, H., Lai, C. T., et al. (2023) · Journal of Hepatology · doi:10.1016/s0168-8278(23)00482-8 · Cited by 8 · see citing works

Identification of Fatty Liver With Advanced Fibrosis in Type 2 Diabetes Using Simple Fibrosis Scores and Electronic Reminder Messages

(2020) · Case Medical Research · doi:10.31525/ct1-nct04241575

Reduced and more appropriate referrals of patients with type 2 diabetes using liver stiffness measurement compared to FIB-4

Shanahan, W., Bagwe, I., Brassill, M. J., & O’Regan, P. (2022) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-022-03019-5 · Cited by 1 · see citing works

Embedding assessment of liver fibrosis into routine diabetic review in primary care

Mansour, D., Grapes, A., Herscovitz, M., Cassidy, P., Vernazza, J., Broad, A., Anstee, Q. M., & McPherson, S. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100293 · Cited by 52 · see citing works

DiabetesLiver score: A non-invasive algorithm for advanced liver fibrosis and liver-related outcomes in type 2 diabetes mellitus population

Liu, C., Shen, J., Li, J., Li, Z., Zheng, M., Bian, H., Zhou, X., Ni, W., Meng, Z., Lv, J., et al. (2025) · Med · doi:10.1016/j.medj.2025.100700 · Cited by 3 · see citing works